CD5-positive marginal zone lymphoma: Clinicopathological features and survival outcomes
Yaqin Xia1, Jurui Ge1, Zhenchang Sun1
1Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China; Lymphoma Diagnosis and Treatment Center of Henan Province, Zhengzhou, Henan, China.
Background:
CD5 expression in different B-cell lymphomas has different clinicopathological and prognosis and the value of CD5 expression in marginal zone lymphoma is undefined.
Methods:
Clinicopathological features, survival outcomes of marginal zone lymphoma were retrospectively analyzed in 204 patients. We classified patients into (i) CD5-positive marginal zone lymphoma (ii) CD5-negative marginal zone Lymphoma, Fisher's exact test was used to compare the CD5-positive and CD5-negative marginal zone lymphoma. Progression-free survival (PFS) and overall survival (OS) curves were summarized by Kaplan-Meier method and compared using the log-rank test.
Results:
Of the 204 patients, 48 (23.53%) were CD5-positive. The 5-year PFS and OS rates for CD5-positive marginal zone lymphoma were 64.80% and 84.10%, there was no significant difference between CD5-positive and CD5-negative (P > 0.05). Diffuse large B cell lymphoma (DLBCL) transformation was pathologically indicated in 6 patients, of which 5 (83.33%) patients were CD5-positive marginal zone lymphoma.
Conclusion:
CD5 expression in marginal zone lymphoma is not relevant to the prognosis of the patients, but CD5-positive marginal zone lymphoma seems more likely to transformation to diffuse large B-cell lymphoma.
